Transglutaminase activation in neurodegenerative diseases
View/ Open
Issue Date
2010-05-01Author
Jeitner, Thomas M.
Muma, Nancy A.
Battaile, Kevin P.
Cooper, Arthur J. L.
Publisher
Future Medicine
Type
Article
Article Version
Scholarly/refereed, author accepted manuscript
Metadata
Show full item recordAbstract
The following review examines the role of calcium in promoting the in vitro and in vivo activation of transglutaminases in neurodegenerative disorders. Diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease exhibit increased transglutaminase activity and rises in intracellular calcium concentrations, which may be related. The aberrant activation of transglutaminase by calcium is thought to give rise to a variety of pathological moieties in these diseases, and the inhibition has been shown to have therapeutic benefit in animal and cellular models of neurodegeneration. Given the potential clinical relevance of transglutaminase inhibitors, we have also reviewed the recent development of such compounds.
Collections
- Pharmacy Scholarly Works [293]
Citation
Jeitner, Thomas M., Nancy A. Muma, Kevin P. Battaile, and Arthur Jl Cooper. "Transglutaminase Activation in Neurodegenerative Diseases." Future Neurology 4.4 (2009): 449-67.
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.